<DOC>
	<DOCNO>NCT01756807</DOCNO>
	<brief_summary>Evaluation Endothelial ProGenitor Cell Capture Sirolimus-Eluting Stent Optical Coherence Tomography : COMBO Stent angiographic extension Study ( EGO-COMBO angiographic extension Study )</brief_summary>
	<brief_title>EGO-COMBO Angiographic Extension Study</brief_title>
	<detailed_description>The Genous Stent ( EPC Capture R-stent , OrbusNeich Medical Inc. , Fort Lauderdale , FL ) commercially available use extensively standard coronary intervention treatment 200 patient critical coronary stenosis Queen Mary Hospital . The COMBO Stent ( OrbusNeich Medical Inc. , Fort Lauderdale , FL ) improve version Genous Stent implant 60 patient Queen Mary Hospital . All patient remain good condition since treatment . The Genous Stent bio-engineered 316L stainless steel coronary stent biocompatible coat specific CD34 antibody inner surface . CD34 surface antigen present circulate endothelial progenitor cell ( EPC ) . It bond CD34 antibody , result capture EPC onto stent surface differentiation endothelial layer . Animal model demonstrate functional endothelial layer could form soon 24 48 hour Genous stent implantation ( 1 ) . The HEALING-FIM registry show Genous stent clinically safe effective treatment coronary stenosis ( 2 ) . Recent report confirm efficacy patient acute coronary syndrome require urgent revascularization ( 3,4 ) . The COMBO Stent develop base GENOUS stent platform , addition , also deliver drug call sirolimus treat coronary blood vessel . The stent 's original CD34 antibody coating design promote heal coronary artery catch circulate endothelial progenitor cell pass stent . These cell naturally flow circulation responsible endothelial healing . This intend help blood vessel wall heal stent quickly restore normal tissue function stented area . The combination two technology new COMBO stent expect produce even well clinical result , investigate previous REMEDEE Study . Animal study show COMBO Stent promote endothelialization reduces neointima formation , assess optical coherence tomography ( OCT ) histopathology ( 5 ) . Even though COMBO Stents use find safe 210 patient world-wide 61 patient Queen Mary Hospital EGO-COMBO Study Protocol , beneficial endothelial coverage assess OCT never document human subject . This current EGO-COMBO angiographic extension study protocol design base approve protocol EGO-COMBO Study ( IRB : UW 10-342 ) . This current study mainly focus time frame , degree endothelialization , subsequent neointimal proliferation COMBO Stent implantation 2 year , assess intracoronary optical coherence tomography ( OCT ) . Intracoronary optical coherence tomography ( OCT ) simple catheter-based imaging technique use optic fibre achieve detail assessment ( resolution 100 micron ) intra-coronary stent apposition , early stent coverage ( endothelialization ) late stent neoinitmal growth ( restenosis ) . It perform part routine cardiac catheterization procedure provide high-resolution cross sectional image coronary artery . OCT show safe clinical practice ( 6 , 7 ) . The C7XR OCT system ( Frequency Domain OCT ) commercial available product CE Mark FDA approval . The OCT catheter non-occlusive optic fibre extremely small flexible pose additional risk patient inherent risk standard angioplasty procedure .</detailed_description>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patient age 1885 year old Patient agree followup coronary angiogram Patient previously enrol EGOCOMBO study Patient refuse consent coronary angiogram coronary angioplasty</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Optical Coherence Tomography</keyword>
	<keyword>Geneous Stent</keyword>
	<keyword>Combo Stent</keyword>
</DOC>